Hikma Pharmaceuticals Management
Management criteria checks 3/4
Hikma Pharmaceuticals' CEO is Riad Mishlawi, appointed in Sep 2023, has a tenure of less than a year. total yearly compensation is $1.55M, comprised of 21.5% salary and 78.5% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth €9.69M. The average tenure of the management team and the board of directors is 3.5 years and 4.9 years respectively.
Key information
Riad Mishlawi
Chief executive officer
US$1.6m
Total compensation
CEO salary percentage | 21.5% |
CEO tenure | less than a year |
CEO ownership | 0.2% |
Management average tenure | 3.5yrs |
Board average tenure | 4.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | US$2m | US$333k | US$190m |
Compensation vs Market: Riad's total compensation ($USD1.55M) is below average for companies of similar size in the German market ($USD3.34M).
Compensation vs Earnings: Insufficient data to compare Riad's compensation with company performance.
CEO
Riad Mishlawi (59 yo)
less than a year
Tenure
US$1,552,833
Compensation
Mr. Riad Ali Mishlawi serves as Chief Executive Officer of Hikma Pharmaceuticals PLC since September 01, 2023 and serves as its Director since September 01, 2023. He had been the President of Injectables s...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman | 16.8yrs | US$3.57m | 0.38% $ 19.2m | |
CEO & Director | less than a year | US$1.55m | 0.19% $ 9.7m | |
Executive Vice Chairman & President of MENA | 18.7yrs | US$2.84m | 0.63% $ 31.3m | |
Chief Financial Officer | 13.3yrs | no data | 0.20% $ 10.1m | |
Chief Information Officer | no data | no data | no data | |
Associate Director of Investor Relations | no data | no data | no data | |
General Counsel | no data | no data | no data | |
Executive Vice President of Corporate Development and M&A | 10.2yrs | no data | 0.28% $ 13.9m | |
Chief People Officer | less than a year | no data | no data | |
Executive Vice President of Strategic Planning & Global Affairs | 6.3yrs | no data | no data | |
Executive Officer | 6.9yrs | no data | no data | |
President of Injectables Business | less than a year | no data | no data |
3.5yrs
Average Tenure
59yo
Average Age
Experienced Management: H5P's management team is considered experienced (3.5 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman | 16.8yrs | US$3.57m | 0.38% $ 19.2m | |
CEO & Director | less than a year | US$1.55m | 0.19% $ 9.7m | |
Executive Vice Chairman & President of MENA | 18.7yrs | US$2.84m | 0.63% $ 31.3m | |
Senior Independent Non-Executive Director | 1.5yrs | US$149.27k | no data | |
Independent Non-Executive Director | 7.6yrs | US$176.38k | 0.0032% $ 159.8k | |
Independent Non-Executive Director | 8.2yrs | US$159.69k | 0.0016% $ 78.9k | |
Non-Executive Director | 18.6yrs | US$116.72k | 0.52% $ 26.2m | |
Independent Non-Executive Director | 4yrs | US$149.85k | 0.0020% $ 101.4k | |
Independent Non-Executive Director | 1.5yrs | US$127.05k | 0.00045% $ 22.5k | |
Independent Non-Executive Director | 4.9yrs | US$134.68k | 0.00050% $ 25.0k | |
Chairman of West-ward Pharmaceuticals | no data | no data | no data | |
Independent Non-Executive Director | 1.6yrs | US$124.98k | no data |
4.9yrs
Average Tenure
65yo
Average Age
Experienced Board: H5P's board of directors are considered experienced (4.9 years average tenure).